Kopran Limited (IN:KOPRAN)
:KOPRAN
Want to see IN:KOPRAN full AI Analyst Report?
Top Page
Kopran Limited
(KOPRAN)
Select Model
Select Model
Rating:62Neutral
Price Target:
₹200.00
▲(31.41% Upside)
Action:Reiterated
Date:05/26/26
The score is driven down primarily by weak cash-flow quality (negative free cash flow) and uneven profitability, partially offset by a constructive technical uptrend and a moderate valuation with a small dividend yield.
Positive Factors
Diversified business model (APIs, formulations, contract manufacturing)
Kopran's mix of finished dosage formulations, APIs and contract manufacturing creates multiple revenue channels and market exposures. This structural diversification reduces reliance on any single product or geography, supporting revenue resilience and strategic flexibility over the next 2–6 months.
Negative Factors
Persistent negative free cash flow
Sustained negative free cash flow points to heavy capex or working-capital drag that erodes internal funding. Over months this reduces financial flexibility, increases dependence on external financing, and constrains the company's ability to deleverage, pay dividends, or fund strategic initiatives.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified business model (APIs, formulations, contract manufacturing)
Kopran's mix of finished dosage formulations, APIs and contract manufacturing creates multiple revenue channels and market exposures. This structural diversification reduces reliance on any single product or geography, supporting revenue resilience and strategic flexibility over the next 2–6 months.
Read all positive factors
Kopran Limited (KOPRAN) vs. iShares MSCI India ETF (INDA)
Market Cap
₹9.16B
Dividend Yield1.96%
Average Volume (3M)13.07K
Price to Earnings (P/E)35.7
Beta (1Y)1.55
Revenue Growth8.23%
EPS Growth-33.30%
CountryIN
Employees842
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)3.65
Shares Outstanding48,285,606
10 Day Avg. Volume27,236
30 Day Avg. Volume13,071
Financial Highlights & Ratios
PEG Ratio-0.61
Price to Book (P/B)0.98
Price to Sales (P/S)0.77
P/FCF Ratio-49.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kopran Limited Business Overview & Revenue Model
Company Description
Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes...
How the Company Makes Money
Kopran Limited makes money primarily by selling pharmaceutical products across two main categories: (1) finished dosage formulations (e.g., tablets, capsules and other dosage forms) and (2) active pharmaceutical ingredients (APIs) used to manufact...
Kopran Limited Financial Statement Overview
Summary
Income Statement
56
Neutral
Balance Sheet
70
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.92B | 6.81B | 6.30B | 6.15B | 5.48B | 4.74B |
| Gross Profit | 2.09B | 1.60B | 2.25B | 2.09B | 1.86B | 1.90B |
| EBITDA | 485.63M | 779.00M | 729.00M | 868.18M | 548.77M | 980.11M |
| Net Income | 175.99M | 257.31M | 385.52M | 509.56M | 272.33M | 610.31M |
Balance Sheet | ||||||
| Total Assets | 8.13B | 9.08B | 8.44B | 7.43B | 6.50B | 6.11B |
| Cash, Cash Equivalents and Short-Term Investments | 372.08M | 72.22M | 258.64M | 80.91M | 73.97M | 58.68M |
| Total Debt | 1.57B | 1.53B | 1.48B | 992.28M | 752.38M | 745.49M |
| Total Liabilities | 3.12B | 3.78B | 3.26B | 2.52B | 2.10B | 1.85B |
| Stockholders Equity | 5.01B | 5.30B | 5.18B | 4.91B | 4.39B | 4.26B |
Cash Flow | ||||||
| Free Cash Flow | 234.30M | -105.46M | -134.46M | -133.56M | -270.22M | -757.47M |
| Operating Cash Flow | 553.87M | 565.79M | 419.42M | 432.58M | 340.23M | -334.75M |
| Investing Cash Flow | -335.65M | -648.97M | -564.28M | -435.52M | -126.50M | -844.15M |
| Financing Cash Flow | -107.78M | -104.72M | 258.68M | 9.88M | -198.44M | 1.23B |
Kopran Limited Technical Analysis
Positive
152.20
Price Trends
173.61
Positive
151.24
Positive
153.07
Positive
Market Momentum
6.11
Positive
54.19
Neutral
49.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Positive. The current price of 152.2 is below the 20-day moving average (MA) of 189.04, below the 50-day MA of 173.61, and below the 200-day MA of 153.07, indicating a bullish trend. The MACD of 6.11 indicates Positive momentum. The RSI at 54.19 is Neutral, neither overbought nor oversold. The STOCH value of 49.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:KOPRAN.
Kopran Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
75 Outperform | ₹116.06B | 27.95 | ― | 0.44% | 12.51% | 9.82% | |
71 Outperform | ₹77.39B | 24.84 | ― | 4.73% | -12.98% | -21.81% | |
69 Neutral | ₹1.16T | 29.96 | ― | 0.87% | 2.23% | -26.44% | |
64 Neutral | ₹18.38B | 37.61 | ― | 0.13% | 36.08% | 130.40% | |
62 Neutral | ₹9.16B | 35.71 | ― | 1.96% | 8.23% | -33.30% | |
57 Neutral | ₹35.24B | 33.33 | ― | 0.13% | 13.30% | 39.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:KOPRAN
Kopran Limited
189.65
7.12
3.90%
IN:CIPLA
Cipla Ltd
1,440.30
-48.47
-3.26%
IN:MARKSANS
Marksans Pharma Limited
256.10
4.69
1.87%
IN:NGLFINE
NGL Fine-Chem Ltd.
2,975.85
1,934.60
185.80%
IN:SANOFI
Sanofi India Limited
3,360.55
-2,648.29
-44.07%
IN:SMSPHARMA
SMS Pharmaceuticals Limited
376.25
127.99
51.55%
Kopran Limited Corporate Events
Kopran Closes Trading Window Ahead of FY26 Results
Mar 24, 2026
Kopran Limited has announced the closure of its trading window for directors, designated persons and their immediate relatives from 1 April 2026 until 48 hours after the declaration of its audited financial results for the fourth quarter and full ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.